A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin.

OBJECTIVE To review and summarize the body of literature regarding human intravenous immunoglobulin (hIVIG) therapy in veterinary medicine. Mechanism of action, usage in human medicine, adverse effects of therapy, implications for veterinary use, and administration recommendations are discussed. DATA SOURCES Current human and veterinary peer-reviewed medical literature including original research articles and scientific reviews. HUMAN DATA SYNTHESIS There are currently 6 labeled uses for hIVIG in human medicine, but preparations are used off-label to successfully treat multiple immune-mediated conditions. To maximize the potential of hIVIG use in animals and identify areas deficient in research, a review of the current literature is warranted. VETERINARY DATA SYNTHESIS Investigation of hIVIG therapy in veterinary patients has been limited to the subjects of immune-mediated hemolytic anemia (IMHA), immune-mediated thrombocytopenia (ITP), Evan's syndrome, cutaneous disease, myasthenia gravis (MG), and sudden acquired retinal degeneration (SARDS). Proponents of veterinary hIVIG use believe administration may reduce transfusion requirements and decrease hospitalization time. CONCLUSION Immunoglobulin (Ig) has not been shown to decrease transfusion requirements in IMHA patients, but shows great promise for treatment of ITP and dermatological diseases. Although serial transfusion of hIVIG is employed in human medicine, repeated transfusion is not recommended in animals due to risk of severe allergic reaction. Other potential adverse effects of transfusion include delayed hypersensitivity reactions, thromboembolism, renal failure, hypotension, and aseptic meningitis.

[1]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. , 2013, The Cochrane database of systematic reviews.

[2]  J. Callum,et al.  Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes , 2010, Transfusion medicine.

[3]  M. Scott,et al.  Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs. , 2009, Journal of veterinary internal medicine.

[4]  P. J. Armstrong,et al.  A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. , 2009, Journal of veterinary internal medicine.

[5]  Megan F. Whelan,et al.  Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. , 2009, Journal of veterinary emergency and critical care.

[6]  R. Hardy,et al.  Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog. , 2009, Journal of the American Animal Hospital Association.

[7]  Megan F. Whelan,et al.  Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia. , 2009, Journal of veterinary emergency and critical care.

[8]  J. Kirmse.  The Nurse's Role in Administration of Intravenous Immunoglobulin Therapy , 2009, Home healthcare nurse.

[9]  S. Grozdanic,et al.  Antibody-mediated retinopathies in canine patients: mechanism, diagnosis, and treatment modalities. , 2008, The Veterinary clinics of North America. Small animal practice.

[10]  P. J. Armstrong,et al.  Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. , 2007, Journal of veterinary internal medicine.

[11]  L. Zinman,et al.  IV immunoglobulin in patients with myasthenia gravis , 2007, Neurology.

[12]  J. Keating,et al.  The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog. , 2006, Journal of veterinary internal medicine.

[13]  I. Marie,et al.  Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.

[14]  U. Giger,et al.  Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. , 2006, Journal of the American Animal Hospital Association.

[15]  O. Abdel-Wahab,et al.  Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature , 2006, Transfusion.

[16]  D. Ward,et al.  Evaluation of canine serum for the presence of antiretinal autoantibodies in sudden acquired retinal degeneration syndrome. , 2006, Veterinary ophthalmology.

[17]  Y. Shoenfeld,et al.  Intravenous immunoglobulin , 2005, Clinical reviews in allergy & immunology.

[18]  P. Boros,et al.  High dose intravenous immunoglobulin treatment: Mechanisms of action , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  E. Gelfand.  Critical Decisions in Selecting an Intravenous Immunoglobulin Product , 2005, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

[20]  R. Ober,et al.  Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.

[21]  A. Shibata,et al.  Single high-dose intravenous immunoglobulin therapy for kawasaki disease increases plasma viscosity. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[22]  Elyse Murphy,et al.  Developing Practice Guidelines for the Administration of Intravenous Immunoglobulin , 2005, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

[23]  R. Lemieux,et al.  Therapeutic intravenous immunoglobulins. , 2005, Molecular immunology.

[24]  Ó. Asensio,et al.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. , 2004, The Journal of allergy and clinical immunology.

[25]  T. Nuttall,et al.  Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. , 2004, The Journal of small animal practice.

[26]  M. Sato,et al.  IgG Anti-IgA Subclasses in Common Variable Immunodeficiency and Association with Severe Adverse Reactions to Intravenous Immunoglobulin Therapy , 2004, Journal of Clinical Immunology.

[27]  G. Dickneite,et al.  Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[28]  A. Berghold,et al.  Low-Dose Versus High-Dose Immunoglobulin for Primary Treatment of Acute Immune Thrombocytopenic Purpura in Children: Results of a Prospective, Randomized Single-Center Trial , 2003, Journal of pediatric hematology/oncology.

[29]  M. Kruskall,et al.  Intravenous immune globulins: an update for clinicians , 2003, Transfusion.

[30]  A. Ahmed,et al.  Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. , 2003, Archives of dermatology.

[31]  R. Kirsner,et al.  Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. , 2003, Archives of dermatology.

[32]  R. S. Padilla,et al.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. , 2003, Archives of dermatology.

[33]  M. Hässig,et al.  Anwendung von humanem Immunglobulin bei Hunden mit primärer immunbedingter hämolytischer Anämie , 2002 .

[34]  F. Chiarini,et al.  The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders , 2002, Neurological Sciences.

[35]  U. Giger,et al.  Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. , 2002, Journal of the American Veterinary Medical Association.

[36]  U. Giger,et al.  Use of human immunoglobulin for treatment of severe erythema multiforme in a cat. , 2002, Journal of the American Veterinary Medical Association.

[37]  M. Hässig,et al.  [Use of human intravenous immunoglobulin in dogs with primary immune mediated hemolytic anemia]. , 2002, Schweizer Archiv fur Tierheilkunde.

[38]  A. Bridges,et al.  Intravenous immune globulin: fighting antibodies with antibodies. , 2001, Journal of the American Academy of Dermatology.

[39]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[40]  J. Keltner,et al.  Clinical and Immunologic Characteristics of Melanoma-Associated Retinopathy Syndrome: Eleven New Cases and a Review of 51 Previously Published Cases , 2001, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[41]  M. Stella,et al.  Toxic Epidermal Necrolysis Treated with Intravenous High-Dose Immunoglobulins: Our Experience , 2001, Dermatology.

[42]  C. Barton,et al.  Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). , 2001, Journal of the American Veterinary Medical Association.

[43]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis and septic shock. , 2002, The Cochrane database of systematic reviews.

[44]  T. Ratko,et al.  A Multicenter Drug Use Surveillance of Intravenous Immunoglobulin Utilization in US Academic Health Centers , 2000, The Annals of pharmacotherapy.

[45]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[46]  J. Guy,et al.  Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. , 1999, Archives of ophthalmology.

[47]  L. Glickman,et al.  Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. , 1998, American journal of veterinary research.

[48]  C. Naspitz,et al.  Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with antibody deficiency syndromes. , 1998, Sao Paulo medical journal = Revista paulista de medicina.

[49]  R. Dubielzig,et al.  Photoreceptor cell death by apoptosis in dogs with sudden acquired retinal degeneration syndrome. , 1998, American journal of veterinary research.

[50]  S. Whittaker,et al.  Dermatological uses of high-dose intravenous immunoglobulin. , 1998, Archives of dermatology.

[51]  D. Bruyette,et al.  Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. , 1997, Journal of veterinary internal medicine.

[52]  M. Perazella,et al.  Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. , 1997, Journal of the American Society of Nephrology : JASN.

[53]  J. C. Scott-Moncrieff,et al.  Human intravenous immunoglobulin therapy. , 1997, Seminars in veterinary medicine and surgery.

[54]  P. Snyder,et al.  Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. , 1997, Journal of the American Veterinary Medical Association.

[55]  J. C. Scott-Moncrieff,et al.  Treatment of nonregenerative anemia with human gamma-globulin in dogs. , 1995, Journal of the American Veterinary Medical Association.

[56]  Rasmussen Je.  Erythema multiforme, Stevens-Johnson Syndrome, and toxic epidermal necrolysis. , 1995 .

[57]  M. Dalakas,et al.  Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors , 1994, Annals of Internal Medicine.

[58]  C. Duhem,et al.  Side-effects of intravenous immune globulins. , 1994, Clinical and experimental immunology.

[59]  V. Affolter,et al.  Cutaneous Drug Reactions: a Retrospective Study of Histopathological Changes and their Correlation with the Clinical Disease , 1992 .

[60]  Lennart Hammarstrom,et al.  Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion , 1991, The Lancet.

[61]  S. Ettinger.  Textbook of Veterinary Internal Medicine , 1989 .

[62]  C. Murphy,et al.  Anti-retinal immunoglobulins in canine ocular diseases. , 1988, Seminars in veterinary medicine and surgery.